EGFR and non-small cell lung carcinoma: On EGFR mutant NSCLC, it is possible that PD-1 inhibitors are ineffective due to the fact that: NSCLC individuals with EGFR wild-type and high levels of PD-L1 expression may benefit better from immune checkpoint blockade therapy than standard chemotherapy (71–73).